Zacks Investment Research on MSN
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.18 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to a loss of $5.12 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback